Boothbay Fund Management’s Vor Biopharma VOR Stock Holding History

Boothbay Fund Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	558,702 +3,000	+0.5%	+$45.4K	0.14%	159
2026 Q1	$9.91M	Buy	+555,702	New	+$7.84M	0.13%	137
2023 Q2	–	Sell	-977	Closed	-$105K	–	2330
2023 Q1	$105K	Buy	977 +261	+36%	+$28.9K	﹤0.01%	1917
2022 Q4	$95.2K	Buy	+716	New	+$70.8K	﹤0.01%	1799

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Boothbay Fund Management's VOR Position: Q2 2026 in Review

Boothbay Fund Management increased its Vor Biopharma (VOR) stake by 0.54% in Q2 2026, buying an estimated $45.4K and bringing the position to 558,702 shares worth $10.3M. The position accounts for 0.14% of the portfolio, ranked #159.

Boothbay Fund Management first reported a position in VOR in Q4 2022 and has held it in 4 quarters since. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Boothbay Fund Management held 558,702 shares of Vor Biopharma worth $10.3M as of Q2 2026.
Boothbay Fund Management bought 3,000 Vor Biopharma shares in Q2 2026, an estimated $45.4K.
Vor Biopharma made up 0.14% of Boothbay Fund Management's portfolio in Q2 2026, its #159 holding.
Boothbay Fund Management first reported a position in Vor Biopharma in Q4 2022 and has held it in 4 quarters since.
102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.